Vietri Maria Teresa, D'Elia Giovanna, Caliendo Gemma, Casamassimi Amelia, Resse Marianna, Passariello Luana, Cioffi Michele, Molinari Anna Maria
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via L. De Crecchio, 7, 80138 Naples, Italy; U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
U.O.C. Clinical and Molecular Pathology, A.O.U. University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Cancer Genet. 2020 Jun;244:32-35. doi: 10.1016/j.cancergen.2020.04.074. Epub 2020 Apr 28.
Familial adenomatous polyposis (FAP) is a rare genetic disorder caused mainly by monoallelic mutations of APC gene. The hereditary breast and ovarian cancer (HBOC) syndrome is an autosomal dominantly inherited disease, which mostly predisposes to breast and ovarian cancers as a result of germline mutations in BRCA1 or BRCA2 genes. In a family, mutations in two cancer susceptibility genes are extremely rare. We studied a family with a case of a 46 years-old woman affected with FAP and ovarian cancer. The patient was affected with profuse FAP since the age of 18 years and a serous ovarian cancer was diagnosed at the age of 45 years. She reported other FAP cases and one case of breast cancer in maternal family. Initially, she was tested for FAP predisposition with mutational analysis of APC gene that revealed the presence of a frameshift mutation, c.3927_3931delAAAGA (p.Glu1309AspfsX4). The presence of ovarian cancer in the patient and of a breast cancer case in the maternal family, suggested an extended analysis to HBOC susceptibility genes that led to the detection of a frameshift mutation, c.3756_3759delGTCT (p.Ser1253Argfs), in BRCA1 gene. The genetic analysis was extended also to family members. The occurrence of the double mutation in APC and BRCA1 genes in the patient was responsible for the onset of FAP and ovarian cancer respectively. The genetic counselling in hereditary cancer with a careful analysis of the pedigree allows identifying the gene to be analyzed. The development of multi-gene panels testing for cancer predisposition, with next generation sequencing (NGS), may reveal mutations in genes of high and moderate penetrance for cancer, although at a low frequency and allows diagnosing a possible double heterozygosity. This enables an adjusted treatment for the affected patient and is critical as it allows initiation of early risk-reducing measures for identified mutation carriers among family members.
家族性腺瘤性息肉病(FAP)是一种罕见的遗传性疾病,主要由APC基因的单等位基因突变引起。遗传性乳腺癌和卵巢癌(HBOC)综合征是一种常染色体显性遗传病,主要由于BRCA1或BRCA2基因的种系突变而易患乳腺癌和卵巢癌。在一个家族中,两个癌症易感基因发生突变极为罕见。我们研究了一个家族,该家族中有一名46岁患有FAP和卵巢癌的女性。该患者自18岁起就患有严重的FAP,45岁时被诊断出患有浆液性卵巢癌。她报告说在母系家族中有其他FAP病例和一例乳腺癌。最初,通过对APC基因的突变分析对她进行了FAP易感性检测,结果显示存在一个移码突变,即c.3927_3931delAAAGA(p.Glu1309AspfsX4)。患者患有卵巢癌以及母系家族中有乳腺癌病例,这表明需要对HBOC易感基因进行进一步分析,结果在BRCA1基因中检测到一个移码突变,即c.3756_3759delGTCT(p.Ser1253Argfs)。基因分析也扩展到了家族成员。患者APC和BRCA1基因中的双重突变分别导致了FAP和卵巢癌的发病。对遗传性癌症进行遗传咨询并仔细分析家系,有助于确定需要分析的基因。通过下一代测序(NGS)进行癌症易感性多基因检测,可能会发现癌症高、中度外显率基因中的突变,尽管其频率较低,并且能够诊断可能的双重杂合性。这使得能够对受影响的患者进行调整治疗,并且至关重要的是,它能够为家族成员中已确定的突变携带者启动早期降低风险的措施。